A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

To join this study, you need to be at least 12 years old and have been diagnosed with Hidradenitis Suppurativa (HS) for at least six months. Your HS should be moderate to severe, meaning you have a certain number of painful lumps and bumps, and it affects at least two different body areas. Importantly, you must have already tried and not found enough relief from at least one type of anti-TNF treatment.

Things that might prevent you from joining include having other active skin infections that could make it hard to check your HS, or if you've recently taken other experimental drugs. You also shouldn't have had certain strong cell-targeting treatments in the past year, or have recently used certain skin creams or antibiotics for your HS or other inflammatory conditions.

If you join this study, you will take tablets either of upadacitinib or a dummy pill (placebo) once a day. This will continue for about 36 weeks in the first part of the study. Depending on your progress, you might then continue with daily tablets for another 68 weeks in the long-term part of the study. In total, your participation will involve taking medication for up to 104 weeks.

You will need to attend regular visits to a clinic. During these visits, medical staff will check your health, assess your HS symptoms, and look out for any side effects. You'll also be asked to complete questionnaires about how you're feeling and how the treatment is affecting you. After you stop taking the study medication, there will be a final check-up about 30 days later. You might find you have more appointments and assessments than you would with your usual HS care.